Fenofibric acid - Hanmi Pharmaceutical

Drug Profile

Fenofibric acid - Hanmi Pharmaceutical

Alternative Names: HIP-0901

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperlipidaemics; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO, Capsule)
  • 05 Apr 2013 Hanmi Pharmaceutical Company completes a phase I trial in Hyperlipidaemia (volunteers) in South Korea (NCT01555398)
  • 01 Dec 2011 Hanmi Pharmaceutical completes enrolment in its phase I trial for Hyperlipidaemia (in volunteers) in South Korea (NCT01509196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top